The latest trading session saw Medtronic (MDT) ending at $87.72, denoting a -0.45% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of 0.38%. Meanwhile, ...

Walton Lillehei, turned to Medtronic founder Earl Bakken for help, to make sure he wouldn’t find himself in this situation ...

A lawsuit against pulse oximeter manufacturers and distributors is starting to create change. But experts say the FDA needs ...

Roots Community Health has sued 12 other firms, including GE Healthcare, CVS and Walgreens, and called for manufacturers and ...

Medtronic and Recor Medical each announced separate Medicare reimbursement approvals for their respective renal denervation ...

Minneapolis, Minnesota-based Medtronic plc (MDT) develops, manufactures, and sells device-based medical therapies to ...

Baxter will share an update on Hurricane Helene’s impact, while Medtronic will likely discuss a new pulsed field ablation ...

Medtronic is modestly undervalued based on DCF analysis, but slow revenue growth limits upside potential. Read why I ...

Medtronic and Recor Medical, Inc. (and its parent company, Otsuka Medical Devices Co., Ltd.) separately and independently ...

Medtronic (NYSE:MDT) today announced new, long-term study data further supporting its Symplicity Spyral renal denervation ...

Patient and physician education is the next challenge to change the treatment paradigm for drug-resistant hypertension, Citi Research analyst Joanne Wuensch said.

Medtronic, a global leader in healthcare technology, unveiled results from the Prospective Registry for Assessment of Acute ...